Table 6.
Analysis of toxicity and adverse reactions.
| Adverse Reaction | Baseline | 3 Months Post-TARE | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Laboratory Abnormalities | ||||||||
| AST Elevation | 9 | 10 | 1 | |||||
| ALT Elevation | 6 | 6 | 1 | |||||
| Hypoalbuminemia | 9 | 7 | 7 | 10 | 4 | |||
| Elevated Alkaline Phosphatase | 16 | 5 | 4 | 4 | ||||
| Hyperbilirubinemia | 5 | 5 | 12 | 2 | 2 | |||
| Hyponatremia | 4 | 5 | 1 | |||||
| Elevated INR | 3 | 1 | 3 | 2 | ||||
| Complications | ||||||||
| REILD | 1 | |||||||
| PUD | 2 | |||||||
AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; TARE, trans-arterial radioembolization; REILD, radioembolization-induced liver disease; PUD, peptic ulcer disease.